Effects of Colesevelam HCl On Bile Acid Kinetics

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This project will compare the amount of bile acids and their kinetics in overweight and obese people with normal glucose metabolism, impaired glucose tolerance and frank type 2 diabetes. We hypothesize that bile acids will behave differently in these groups. We will also explore the effects of Colesevelam HCl, a medicine that lowers LDL cholesterol by binding bile acids, on bile acids in those groups. We hypothesize the drug may have different actions on bile acids in subjects with different degrees of abnormal glucose metabolism.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: KineMed
• Collaborators: Daiichi Sankyo Inc.; Daiichi Sankyo, Inc.; Diabetes & Glandular Disease Research Associates; University Medical Center Groningen
• Treatments: Bile Acids and Salts; Colesevelam Hydrochloride

Criteria

Inclusion Criteria:

• Have given written informed consent

• BMI 25-35 kg/m^2, inclusive

• Normal liver and thyroid function

• No history of liver, biliary, or intestinal disease

Diabetic Subjects

• Diagnosed Type 2 Diabetes Mellitus

• HbA1C = 6.7-10%

Normal Subjects

• 2 hr OGTT glucose < 140 mg/dL

• fasting glucose < 100 mg/dL

• TG < 150 mg/dL

• HDL cholesterol >= 40 mg/dL

Impaired Glucose Tolerance Subjects

• 2 hr OGTT glucose >= 140 and < 200 mg/dL

Exclusion Criteria:

• T1DM or history of diabetic ketoacidosis

• treatment with blood pressure lowering therapy that has not been stable for three months before screening

• colesevelam HCl, cholestyramine, or colestipol treatment for hyperlipidemia within the last three months

• treatment with thiazolidinedione (TZD) at any time

• treatment with insulin within past 6 months

• treatment with antibiotics within last 3 months

• extreme sportsmen

• treatment with medication affecting liver or intestinal function within the last 3 months

• allergic or toxic rxn to colesevelam HCl

• history of dysphagia, swallowing disorders, or intestinal motility disorder

• Serum Triglycerides > 500 mg/dL at visit 1

• Serum LDL-C < 60 mg/dL at visit 1

• any condition or therapy investigator believes not in subjects best interest

• use of any investigational drug within 30 days before screening

• chronic treatment with oral corticosteroids at any time or acute treatment within last three months

• hyperthyroidism or treatment with thyroid hormone/levothyroxine